This compound is a thalidomide analog primarily utilized in the development of pharmaceuticals, particularly immunomodulatory drugs (IMiDs) for cancer therapy, such as multiple myeloma. It serves as a key intermediate in the synthesis of cereblon ligands that induce the ubiquitination and subsequent proteasomal degradation of target proteins, like transcription factors, in cancer cells. This mechanism disrupts the growth and survival of malignant cells, making it valuable in oncology research. Additionally, it has potential applications in the study of neurodegenerative diseases, where targeted protein degradation pathways play a significant role. Its unique chemical structure enables specific interactions with E3 ubiquitin ligases, contributing to advancements in therapeutic drug development, including PROTACs and other protein degraders.